CMV AND EBV REACTIVATION AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (EBMT 2026) - Mar 14, 2026 - Abstract #B113; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "Regarding GVHD prophylaxis, anti-thymocyte globulin (ATG) was used in 83.8% (n=62) of patients, and post-transplant cyclophosphamide (PTCy) was used in 17.6% (n=13). For pre-transplant antiviral prophylaxis, ganciclovir was administered to 89.2% (n=66) of patients and foscarnet to 21.6% (n=16)... In elderly haplo-HCT recipients, EBV reactivation correlates with inferior survival, whereas early CMV reactivation predicts disease relapse without compromising survival. Letermovir prophylaxis effectively mitigates CMV risk but is independently associated with increased EBV reactivation, presenting a clinical trade-off. These findings highlight the distinct prognostic implications of viral kinetics and underscore the necessity for balanced prophylactic strategies and vigilant monitoring in this vulnerable population."
Clinical • Acute Myelogenous Leukemia • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation
|
|
Mengqi Xiang1; Jinjin Zhu1; Jiaxin Li1; Yuhua Ru1; Mimi Xu1; Yuqing Tu1; Yi Fan1; Xiang Zhang1; Aining Sun1; Huiying Qiu1; Zhengming Jin1; Xiaowen Tang1; Yue Han1; Chengcheng Fu1; Suning Chen1; Xiao Ma1; Feng Chen1; Yang Xu1; Tiemei Song1; Depei Wu1; Jia Chen1
|